Bio-Techne Announces Launch of Professional Assay Services - Dedicated Source for RNA in situ Hybridization Assays in Spatial Gene Expression Analysis

MINNEAPOLIS, April 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in response to increased demand for its Assay Services offered at its Newark, CA laboratory. At the heart of this re-launch is a name change from Pharma Assay Services to Professional Assay Services, with an expansion of offerings to global academic and clinical institutions, building on 10 years of experience providing services to our global pharma and biotech partners. Bio-Techne's Professional Assay Services provide
in situ hybridization (ISH) gene expression analysis for target discovery, biomarker validation, drug safety assessment, and assay prototype development directly from the RNAscope™ technology experts.

Related Keywords

Kim Kelderman ,David Clair ,Prnewswire Bio Techne Corporation ,Assay Services ,Investor Relations Corporate Development ,Good Clinical Laboratory Practices ,World Health Organization ,Pharma Assay Services To Professional ,Bio Techne Corporation ,Techne Corporation ,Advanced Cell Diagnostics ,Pharma Assay Services ,Professional Assay Services ,World Health ,Senior Director ,Investor Relations ,கிம் கேள்தேர்மன் ,டேவிட் கிளேர் ,மதிப்பீடு சேவைகள் ,முதலீட்டாளர் உறவுகள் பெருநிறுவன வளர்ச்சி ,நல்ல மருத்துவ ஆய்வகம் ப்ர்யாக்டிஸஸ் ,உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,உயிர் தொழில்நுட்பம் நிறுவனம் ,தொழில்நுட்பம் நிறுவனம் ,உலகம் ஆரோக்கியம் ,மூத்தவர் இயக்குனர் ,முதலீட்டாளர் உறவுகள் ,